As Professor in molecular virology my R&D focus is on the design, development and deployment of viral pseudotype based neutralisation assays for influenza, coronavirus and other emerging viruses. This R&D has been funded by the MRC, the Bill & Melinda Gates Foundation, Innovate UK, the Wellcome Trust, the Rosetrees Trust and the Medway School of Pharmacy.

I am Director of the Viral Pseudotype Unit (VPU) within the University of Kent Medway School of Pharmacy, a purpose built, dedicated viral pseudotype R&D laboratory. The role of the VPU is to act as an interface between academia, industry, animal and public health laboratories with the purpose of translating basic virus research into in vitro cell culture based assays that can be readily employed for the efficacy testing of vaccines, antivirals and therapeutic antibodies. 

I am a recognised global opinion leader in pseudotype virus platform technologies with 175+ peer-reviewed journal and review articles, and over 17,000 citations (h-index = 60). I am a senior consultant for VisMederi (Siena, Italy).